Fall IPO flurry as biotechs ramp up listing timelines

Four biotechs set terms for U.S. IPOs Monday in a month that has already seen five go public, including the largest raise of the year. Collectively, the quartet could raise over $500 million.

ADC Therapeutics S.A. proposed to sell 8.2 million shares at $23-$26 in an offering on the New York Stock Exchange. At the $24.50 midpoint, ADC would raise $200 million and be valued at $1.8 billion.

The antibody-drug conjugate company's pipeline includes three candidates

Read the full 743 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE